Zobrazeno 1 - 10
of 213
pro vyhledávání: '"FM RICHARDS"'
Autor:
Foster, K., Prowse, A., Anke van den Berg, Fleming, S., MMF HULSBEEK, PA CROSSEY, FM RICHARDS, Cairns, P., MA FERGUSONSMITH, CHCM BUYS, ER MAHER
Publikováno v:
Human Molecular Genetics, 3(12), 2169-2173. Oxford University Press
University of Groningen
University of Groningen
Loss of heterozygosity (LOH) studies have suggested that somatic mutations of a tumour suppressor gene or genes on chromosome 3p are a critical event in the pathogenesis of non-familial renal cell carcinoma (RCC). Germline mutations of the von Hippel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ec20db670f8d2bf2f8e39d1f8ca08078
https://research.rug.nl/en/publications/25e85651-3f94-49ca-a1c4-1412502ffbaa
https://research.rug.nl/en/publications/25e85651-3f94-49ca-a1c4-1412502ffbaa
Autor:
Graziano V; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK vincenzo.graziano@astrazeneca.com Duncan.Jodrell@cruk.cam.ac.uk.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK., Dannhorn A; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca R&D, Cambridge, UK., Hulme H; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca R&D, Cambridge, UK., Williamson K; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK., Buckley H; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Karim SA; Cancer Research UK Beatson Institute, Glasgow, UK., Wilson M; Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK., Lee SY; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Kaistha BP; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Islam S; Department of Oncology, University of Cambridge, Cambridge, UK., Thaventhiran JED; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Goodwin R; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca R&D, Cambridge, UK., Brais R; Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Morton JP; Cancer Research UK Beatson Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Dovedi SJ; Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK., Schuller AG; Oncology, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Eyles J; Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK vincenzo.graziano@astrazeneca.com Duncan.Jodrell@cruk.cam.ac.uk.; Department of Oncology, University of Cambridge, Cambridge, UK.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Aug; Vol. 11 (8).
Autor:
Roy-Luzarraga M; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Reynolds LE; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., de Luxán-Delgado B; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Maiques O; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Wisniewski L; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Newport E; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Rajeeve V; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Drake RJG; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Gómez-Escudero J; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Richards FM; Translational Medicine Operations, Astrazeneca Oncology, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, United Kingdom., Weller C; Department of Dermatology, Section of Clinical and Molecular Dermatology, Venereology and Allergology, University Medical Center and European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Dormann C; Department of Dermatology, Section of Clinical and Molecular Dermatology, Venereology and Allergology, University Medical Center and European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Meng YM; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Vermeulen PB; Department of Oncological Research, Translational Cancer Research Unit, Oncology Center GZA-GZA Hospitals St. Augustinus and University of Antwerp, Antwerp, Belgium., Saur D; Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg and Chair of Translational Cancer Research and Institute for Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, München, Germany., Sanz-Moreno V; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Wong PP; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Géraud C; Department of Dermatology, Section of Clinical and Molecular Dermatology, Venereology and Allergology, University Medical Center and European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Cutillas PR; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom., Hodivala-Dilke K; Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom.
Publikováno v:
Cancer research [Cancer Res] 2022 May 16; Vol. 82 (10), pp. 1909-1925.
Autor:
Popov AB; BioNano Engineering Lab, Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK. lf389@cam.ac.uk., Melle F; The Adsorption & Advanced Materials Laboratory (A2ML), Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK., Linnane E; The Adsorption & Advanced Materials Laboratory (A2ML), Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK., González-López C; BioNano Engineering Lab, Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK. lf389@cam.ac.uk.; CRUK Cambridge Centre Early Detection Program, Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge CB2 0RE, UK., Ahmed I; BioNano Engineering Lab, Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK. lf389@cam.ac.uk., Parshad B; BioNano Engineering Lab, Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK. lf389@cam.ac.uk., Franck CO; BioNano Engineering Lab, Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK. lf389@cam.ac.uk., Rahmoune H; Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.; Translational Medicine, Oncology R&D, Astra Zeneca, Cambridge CB4 0WG, UK., Muñoz-Espín D; CRUK Cambridge Centre Early Detection Program, Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge CB2 0RE, UK., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK., Fairen-Jimenez D; The Adsorption & Advanced Materials Laboratory (A2ML), Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK., Fruk L; BioNano Engineering Lab, Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK. lf389@cam.ac.uk.
Publikováno v:
Nanoscale [Nanoscale] 2022 May 05; Vol. 14 (17), pp. 6656-6669. Date of Electronic Publication: 2022 May 05.
Autor:
Strittmatter N; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.; Department of Chemistry, Technical University of Munich, 85748 Garching, Germany., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K.; Translational Medicine, Oncology R&D, Astra Zeneca, Cambridge CB4 0WG, United Kingdom., Race AM; Institute of Medical Bioinformatics and Biostatistics, Philipps University of Marburg, 35032 Marburg, Germany., Ling S; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Sutton D; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Nilsson A; Department of Pharmaceutical Biosciences, Medical Mass Spectrometry Imaging, Uppsala University, 751 24 Uppsala, Sweden.; Science for Life Laboratory, Spatial Mass Spectrometry, Uppsala University, 751 24 Uppsala, Sweden., Wallez Y; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K.; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0RE, United Kingdom., Barnes J; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Maglennon G; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Gopinathan A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K., Brais R; Cambridge University Hospitals NHS Trust, Cambridge CB2 0QQ, United Kingdom., Wong E; Biologics Engineering, R&D, AstraZeneca, Cambridge CB12 6GH, United Kingdom., Serra MP; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Atkinson J; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Smith A; DMPK, Oncology R&D, AstraZeneca, Cambridge CB2 0RE, United Kingdom., Wilson J; DMPK, Oncology R&D, AstraZeneca, Cambridge CB2 0RE, United Kingdom., Hamm G; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Johnson TI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K., Dunlop CR; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K., Kaistha BP; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K.; Clinical IO group, Early Oncology, AstraZeneca, Cambridge CB12 6GH, United Kingdom., Bunch J; National Centre of Excellence in Mass Spectrometry Imaging, National Physical Laboratory, Teddington TW11 0LW, United Kingdom.; Rosalind Franklin Institute, Didcot OX11 0QS, United Kingdom., Sansom OJ; Cancer Research UK Beatson Institute, Glasgow G61 1BD, United Kingdom.; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, United Kingdom., Takats Z; Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, United Kingdom.; Rosalind Franklin Institute, Didcot OX11 0QS, United Kingdom., Andrén PE; Department of Pharmaceutical Biosciences, Medical Mass Spectrometry Imaging, Uppsala University, 751 24 Uppsala, Sweden.; Science for Life Laboratory, Spatial Mass Spectrometry, Uppsala University, 751 24 Uppsala, Sweden., Lau A; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0RE, United Kingdom., Barry ST; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0RE, United Kingdom., Goodwin RJA; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, United Kingdom., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, U.K.; Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, United Kingdom.
Publikováno v:
Analytical chemistry [Anal Chem] 2022 Jan 25; Vol. 94 (3), pp. 1795-1803. Date of Electronic Publication: 2022 Jan 10.
Autor:
Li D; Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland.; Thoracic & GI Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland., Schaub N; Surgery Branch, Center for Cancer Research, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.; Leonard Lawson Cancer Center, Pikeville Medical Center, Pikeville, Kentucky., Guerin TM; Center for Advanced Preclinical Research, Frederick National Laboratories for Cancer Research, NCI, Frederick, Maryland., Bapiro TE; Department of Oncology, University of Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom.; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Richards FM; Department of Oncology, University of Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom., Chen V; CCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Talsania K; CCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Kumar P; Sequencing Facility & Single Cell Analysis Facility, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Gilbert DJ; Center for Advanced Preclinical Research, Frederick National Laboratories for Cancer Research, NCI, Frederick, Maryland., Schlomer JJ; Center for Advanced Preclinical Research, Frederick National Laboratories for Cancer Research, NCI, Frederick, Maryland., Kim SJ; GILO Institute, GILO Foundation, Seoul, Korea., Sorber R; Thoracic & GI Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland.; Department of Surgery, The Johns Hopkins Hospital, Johns Hopkins University, Baltimore, Maryland., Teper Y; Thoracic & GI Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland.; Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California., Bautista W; Center for Advanced Preclinical Research, Frederick National Laboratories for Cancer Research, NCI, Frederick, Maryland., Palena C; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Ock CY; Department of Hematology & Oncology, Seoul National University Hospital, Seoul, Korea., Jodrell DI; Department of Oncology, University of Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom., Pate N; Center for Advanced Preclinical Research, Frederick National Laboratories for Cancer Research, NCI, Frederick, Maryland., Mehta M; Sequencing Facility & Single Cell Analysis Facility, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Zhao Y; CCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Kozlov S; Center for Advanced Preclinical Research, Frederick National Laboratories for Cancer Research, NCI, Frederick, Maryland. kozlovse@mail.nih.gov rudloffu@mail.nih.gov., Rudloff U; Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland. kozlovse@mail.nih.gov rudloffu@mail.nih.gov.; Thoracic & GI Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland.; Surgery Branch, Center for Cancer Research, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Oct; Vol. 20 (10), pp. 1926-1940. Date of Electronic Publication: 2021 Aug 10.
Autor:
Johnson TI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. Electronic address: Isaac.Johnson@cantab.net., Minteer CJ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Kottmann D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Dunlop CR; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Fernández SBQ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Carnevalli LS; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Wallez Y; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK; Department of Oncology, University of Cambridge, Cambridge, UK. Electronic address: dij21@cam.ac.uk.
Publikováno v:
EBioMedicine [EBioMedicine] 2021 Jun; Vol. 68, pp. 103396. Date of Electronic Publication: 2021 May 25.
Autor:
Biasci D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, CB2 1QW, UK., Smoragiewicz M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Connell CM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK., Wang Z; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724., Gao Y; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724., Thaventhiran JED; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, CB2 1QW, UK., Basu B; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK., Magiera L; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Johnson TI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Bax L; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK., Gopinathan A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Isherwood C; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Gallagher FA; Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK., Pawula M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Hudecova I; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Gale D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Rosenfeld N; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Barmpounakis P; Department of Statistics, Athens University of Economics and Business, 104 34 Athens, Greece., Popa EC; Weill Cornell Medicine, New York, NY 10065., Brais R; Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK., Godfrey E; Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK., Mir F; Clinical Pharmacology Unit, University of Cambridge, CB2 1TN Cambridge, UK., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK., Fearon DT; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK; dfearon@cshl.edu janowitz@cshl.edu.; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.; Weill Cornell Medicine, New York, NY 10065., Janowitz T; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK; dfearon@cshl.edu janowitz@cshl.edu.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.; Northwell Health Cancer Institute, New Hyde Park, NY 11042., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 ORE, UK.; Cancer Research UK Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Nov 17; Vol. 117 (46), pp. 28960-28970. Date of Electronic Publication: 2020 Oct 30.
Autor:
Dunlop CR; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. Charles.Dunlop@cruk.cam.ac.uk., Wallez Y; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Johnson TI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Bernaldo de Quirós Fernández S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Durant ST; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Cadogan EB; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. dij21@cam.ac.uk.; Department of Oncology, University of Cambridge, Cambridge, UK. dij21@cam.ac.uk.
Publikováno v:
British journal of cancer [Br J Cancer] 2020 Oct; Vol. 123 (9), pp. 1424-1436. Date of Electronic Publication: 2020 Aug 03.
Autor:
Buchholz SM; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany., Goetze RG; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany., Singh SK; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany., Ammer-Herrmenau C; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany., Richards FM; Cancer Research UK Cambridge Institute, The University of Cambridge, Li Ka Shing Centre, Cambridge CB2 1TN, UK., Jodrell DI; Cancer Research UK Cambridge Institute, The University of Cambridge, Li Ka Shing Centre, Cambridge CB2 1TN, UK., Buchholz M; Department of Medicine, Division of Gastroenterology, Endocrinology and Metabolism, Philipps University Marburg, 35037 Marburg, Germany., Michl P; Department of Internal Medicine I, Martin-Luther-University of Halle-Wittenberg, 06120 Halle, Germany., Ellenrieder V; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany., Hessmann E; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany., Neesse A; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Publikováno v:
Cancers [Cancers (Basel)] 2020 Jul 20; Vol. 12 (7). Date of Electronic Publication: 2020 Jul 20.